Rabies virus (RABV) maintenance in bats is not well understood. Big brown bats (Eptesicus fuscus), little brown bats (Myotis lucifugus), and Mexican free-tailed bats (Tadarida brasiliensis) are the most common bats species in the United States. These colonial bat species also have the most frequent contact with humans and domestic animals. However, the silver-haired bat (Lasionycteris noctivagans) RABV is associated with the majority of human rabies virus infections in the United States and Canada. This is of interest because silver-haired bats are more solitary bats with infrequent human interaction. Our goal was to determine the likelihood of a colonial bat species becoming infected with and transmitting a heterologous RABV. To ascertain the potential of heterologous RABV infection in colonial bat species, little brown bats were inoculated with a homologous RABV or one of two heterologous RABVs. Additionally, to determine if the route of exposure influenced the disease process, bats were inoculated either intramuscularly (i.m.) or subcutaneously (s.c.) with a homologous or heterologous RABV. Our results demonstrate that intramuscular inoculation results in a more rapid progression of disease onset, whereas the incubation time in bats inoculated s.c. is significantly longer. Additionally, cross protection was not consistently achieved in bats previously inoculated with a heterologous RABV following a challenge with a homologous RABV 6 months later. Finally, bats that developed rabies following s.c. inoculation were significantly more likely to shed virus in their saliva and demonstrated increased viral dissemination. In summary, bats inoculated via the s.c. route are more likely to shed virus, thus increasing the likelihood of transmission.
L
yssavirus infections have been reported in numerous species of terrestrial and flying mammals (1, 2) . Several regions of enzootic rabies virus (RABV) activity occur in raccoon, skunk, and fox populations within the continental United States. These enzootic foci are generally limited to homologous infections; e.g., raccoons are infected with a raccoon rabies virus variant (2) . Despite less geographical isolation, chiropteran RABVs are also typically limited to their host species (3) . However, RABV spillover into heterologous hosts does occur and has been implicated in the origin of raccoon-and skunk-adapted RABVs (4) .
Two of the most common species of bats in the continental Unites States are the big brown bat (Eptesicus fuscus) and the little brown bat (Myotis lucifugus) (5) . These highly colonial species are adapted to living in both urban and rural areas. On the basis of data from public health rabies laboratories, big brown bats and little brown bats are the bat species most commonly submitted for rabies testing. The large number of submissions stems from human or domestic animal exposure (6) . Despite frequent interaction, only three human rabies cases acquired in the United States have been associated with the little brown bat or big brown bat RABV since 1990 (Fox News). The RABV most often associated with human rabies cases acquired in the United States is the silver-haired bat (Lasionycteris noctivagans) RABV (LnRV) (7; http://www.cdc.gov/rabies /location/usa/surveillance/humanrabies.html). Unlike big brown or little brown bats, silver-haired bats are tree-dwelling bats that form small colonies, and thus, human interaction with this species is infrequent (7) . Previous studies have postulated that the silverhaired bat RABV possesses an increased pathogenicity, including the ability to replicate at lower temperatures and infect nonneuronal cell lines (8, 9) . These unique characteristics increase the transmissibility of LnRV, posing a greater exposure risk to more gregarious bat or domestic animal species, thereby increasing the possibility of human-LnRV interaction.
In nature, the amount of RABV and the depth at which it is inoculated in a bite wound vary considerably between bats and terrestrial RABV vector species, such as raccoons, skunks, and foxes. The puncture wounds following a bat bite may easily go unnoticed, yet the bite of a raccoon would likely result in trauma requiring medical attention and thus rabies treatment. Additionally, the depth of inoculation would be greater following the bite of a raccoon than the bite of a bat. Bat bites are less likely to penetrate into muscular tissue, generally resulting in a superficial laceration or subcutaneous (s.c.) exposure. Studies in which bats were inoculated with European bat lyssavirus-1 (EBLV-1) demonstrated the ability of s.c. and intramuscular (i.m.) inoculation of RABV to result in RABV infection and possible transmission (10) . As a result, bat RABV may have an increased ability to infect and replicate in epithelial or subcutaneous tissue.
Is human RABV infection the result of direct contact with a silver-haired bat or another more common bat species or domestic animal that may be infected with LnRV? Although spillover of LnRV into heterologous bat species and domestic animals has been reported, adaptation has not. However, a study comparing heterologous RABV infections among bat species demonstrated that little brown bats were most likely to be infected with a heterologous RABV, including LnRV (3). Thus, heterologous RABV transmission and dissemination among bat species may be more common than previously acknowledged.
To determine the potential of heterologous RABV infection in a colonial bat species, little brown bats (Myotis lucifugus) were inoculated with a homologous or heterologous RABV. Additionally, to determine the influence of the route of exposure on infection and transmissibility, bats were inoculated either i.m. or s.c.
MATERIALS AND METHODS
Ethics statement. The experiments were designed and animal care was done in compliance with the guidelines of the USDA Animal Care and Welfare Act (AWA) and the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The use of bats in this experiment was approved by and conducted in accordance with the Wadsworth Center IACUC.
Animals. Little brown bats were removed from a hibernaculum located in upstate New York. Bats of both genders were quarantined within a biosafety level 3 facility in groups of 5 to 8 for 6 months. All bats entering the captive colony were weighed, and an oral swab specimen was collected. Bats were identified with uniquely colored wing bands. Bats were provided fresh water and ad lib mealworms daily. Bats were given 1 drop of flax seed oil twice a week to prevent dry skin. The room temperature was maintained at 24 to 27°C, and the humidity was approximately 60 to 80%. Twice a week bats were given a brief physical exam and weighed, and an oral swab specimen was obtained. A bat that had lost 0.5 g between examinations was reweighed daily. If weight loss continued, the bat was placed in a smaller isolation cage, monitored more closely, hand-fed mealworms and beef baby food, and, if necessary, administered 0.5 ml lactated Ringer's saline s.c. every 24 h. If a bat was demonstrating clinical signs of rabies and did not improve within 24 to 48 h, it was euthanized, necropsied, and tested for rabies via a direct fluorescent-antibody test (dFAT). Sera were collected to assay for anti-rabies virus neutralizing antibodies (VNAs) as previously described (11) .
One week prior to inoculation, bats were divided into six mixed gender groups of five individuals. Each group was inoculated with 10 4 50% tissue culture infective doses (TCID 50 s) of either little brown bat (Myotis lucifugus) RABV (MlV1), big brown bat (Eptesicus fuscus) RABV (EfV2), or silver-haired bat (Lasionycteris noctivagans) RABV (isolate LnV1) in a volume of 10 l in the right deltoid muscle or the subcutaneous tissues superficial to the right deltoid muscle using a Hamilton syringe and a 30-gauge needle (Table 1) . Inoculations were performed under a magnifying lens/lamp to ensure proper administration of virus. To confirm that each bat was inoculated correctly, multiple checks were established: two individuals verified bat identification, virus variant, and route of inoculation and visualized virus administration. One individual handled the bat, while the other applied the inoculum. Serum was not collected prior to inoculation. Testing of serum prior to RABV inoculation is ideal when working with wild animals, including larger and heartier species of bats, such as big brown bats. However, little brown bats are much smaller, and the amount of serum that can be safely obtained from an ϳ10-g bat may not be adequate for testing. Furthermore, the fragility of little brown bats compelled the researchers to be cautious. Thus, the decision was made that maintaining a healthy colony of little brown bats outweighed the benefits of serum collection.
Serum was not collected from all bats that survived the study. Because of the population decline due to white nose syndrome (WNS), the ability to collect little brown bats for use in laboratory studies is limited. Some of the surviving bats were transferred to a WNS study.
Regardless of the primary inoculum, all surviving wild-caught bats were administered a secondary challenge with 10 4 TCID 50 s MlV1 in 10 l in the right deltoid muscle 6 months after the primary inoculation.
Virus. Virus was isolated from the salivary glands of Myotis lucifugus (MlV1), Eptesicus fuscus (EfV2), and Lasionycteris noctivagans (LnV1) bats (12, 13) . To obtain adequate amounts of virus for inoculation, isolates were passaged in either neuroblastoma (NA) (LnV1, EfV2) or BHK (MlV1) cell lines. To confirm the genotype of RABV, the N gene of the virus isolate was sequenced as previously described (14) .
Oral swabs. Oral swabs were placed in 500 l Eagle's minimum essential medium (EMEM) supplemented with 100 IU penicillin G, 50 g streptomycin, and 2.5 mg amphotericin B per ml. Oral swabs were tested for RABV via virus isolation and PCR. For PCR, RNA was extracted from the oral swab using 200 l of sample added to TRIzol LS reagent and processed per the manufacturer's recommendations (Invitrogen, Carlsbad, CA). The cDNA was generated from extracted RNA as described in the Quanta qScript cDNA synthesis kit (Quanta BioSciences, Gaithersburg, MD) using random primers.
Two hundred microliters of the oral swab suspension was vortexed in a class II biological safety cabinet. Suspensions were centrifuged for 30 min at 4°C and 10,000 rpm. Supernatant (100 l) was placed into a 1-ml microtube, and 200 l of NA cells at a concentration of 5 ϫ 10 5 per ml was added to the suspension. The tube was held at 4°C for 15 to 20 min, and the contents were mixed by inversion every 5 min. One milliliter of oral swab growth medium (OSGM; composed of Eagle's minimum essential medium supplemented with 10% fetal bovine serum, 2.0 mM glutamate, 100 IU penicillin G, 50 g streptomycin, and 2.5 mg amphotericin B per ml) was added to duplicate wells in a 96-well plate. Incubation was in a moist chamber at 34°C with 5% CO 2 for 4 days.
After incubation, one well from each sample was trypsinized, and the contents were seeded into five wells of a new 96-well plate and allowed to grow for 4 days. The OSGM was aspirated from the remaining well; the cell sheet was flooded with 0.01 M phosphate-buffered saline (PBS; pH 7.6) for 1 min to remove the OSGM, the wash was aspirated, and the cell sheet was fixed overnight with methanol-formalin fixative (1:1 100% methanol and 10% formalin solution). Each well received one quick wash followed by two 30-min PBS washes to remove the fixative. Cells were stained with light diagnostics rabies dFAT reagent (catalog no. 5100; Chemicon International, Temecula, CA) for 30 min, followed by two 2-min PBS washes. Before examining the wells on a Zeiss Axiovert 200 fluorescence microscope at magnifications of ϫ200 and ϫ400, each well was flooded with 0.20 ml of 0.85% saline buffered with 0.05 M Trizma, pH 9.0. The blind-passaged plates were fixed, stained, and examined by fluorescence microscopy as described above.
Frozen tissue histology. A full necropsy was performed on any animal that died or was euthanized during the course of the study. A brain tissue sample was collected for routine rabies testing. Multiple tissue samples were collected to assay for the presence of viral antigen and viral RNA. Each tissue sample was divided between two 0.5-ml Sarstedt microtubes (catalog no. 72.730.006) containing 200 l of sterile 0.01 M PBS and stored at Ϫ80°C.
Tissues were cut in 7-m-thick sections on a microtome cryostat (HM 505 N; Microm International GmbH). Two to four sections were flashfrozen and then later thawed and affixed to positively charged slides (catalog no. 12-550-19; Fisher brand Colorfrost Plus). The slides containing sections were air dried for 20 min in a fume hood before acetone fixation or put in short-term storage in a Ϫ20°C freezer.
The protocol for postmortem diagnosis of rabies in animals by dFAT (www.cdc.gov/rabies/pdf/RabiesDFASPv2.pdf) was followed for fixation, staining, and results interpretation. Each tissue specimen was tested with two different rabies virus-specific fluorescein isothiocyanate conjugates (Light Diagnostics DFA1 [catalog no. 5100] and Light Diagnostics DFA3 [catalog no. 5500]; EMD Millipore, Billerica, MA). All conjugates were titrated to determine the optimal working dilution in the Rabies Laboratory at the Wadsworth Center and stored frozen at Ϫ40°C at the working dilution. Conjugates were dispensed using a syringe fitted with a 0.45-m-pore-size syringe filter that contained low-protein-binding membrane material.
Statistical analysis was accomplished using a one-way analysis of variance (ANOVA).
Molecular assay. Using a Precellys 24 homogenizer (Bertin Technology, Rockville, MD), tissues were processed in 800 l TRIzol LS reagent and 200 l growth media. RNA was extracted per the manufacturer's recommendations (Invitrogen, Carlsbad, CA). For conventional PCRs, cDNA was generated from extracted RNA and random primers as de-scribed in the ABI high-capacity cDNA synthesis kit (Applied Biosystems, Carlsbad, CA). A 400-bp region of the RABV N gene was amplified using a Qiagen HotStarTaq DNA polymerase PCR per the manufacturer's protocol (Qiagen, Germantown, MD) and primers 21G (5=-ATGTAACACC CCTACAATG-3=) and 390 (5=-CTTGTCAACTCCATACC-3=) (15) . Amplicons were separated by agarose gel electrophoresis, and the appropriate band from each reaction mixture was excised with a sterile razor blade and purified using spin prep columns (Qiagen, Germantown, MD). The nucleotide sequence of purified PCR products was determined and compared to other RABV nucleotide sequences via BLAST analysis of the sequences in GenBank.
Quantification of viral RNA was accomplished by TaqMan-based quantitative reverse transcriptase PCR (qRT-PCR) as previously described (16) using the RABVD1 probe/primer set. A green fluorescent protein (GFP) mRNA assay was used as an internal extraction and positive control. The real-time assay was performed using a qScrip Fast one-step qRT-PCR kit with Low ROX (Quanta, Gaithersburg, MD) per the manufacturer's recommendations. To identify and avoid inhibition, samples were run undiluted and at 1:10 and 1:100 dilutions. Cycling conditions were as follows: 50°C for 5 min, 95°C for 30 s, and 45 cycles of 95°C for 15 s and 50°C for 1 min. The assay was run on an ABI 7500 real-time PCR system. Our limit of detection (LOD) was 170 gene copies with a threshold cycle of 37. An endpoint standard curve was generated from 10-fold serial dilutions of cDNA of known copy number ranging from 10 8 to 10 2 transcripts. Additionally, a primer/probe set designed to target the spiked internal extraction control GFP was included. Analysis of results was performed using ABI 7500 software. Statistical analysis was accomplished using a one-way ANOVA.
RESULTS
RABV was not detected in the saliva of bats that developed rabies following an i.m. inoculation. To determine if a homologous RABV (MlV1) was more virulent than a heterologous RABV (EfV2, LnV1), five little brown bats were inoculated i.m. with 10 4 TCID 50 s of either MlV1, EfV2, or LnV1. Oral swab specimens were collected twice a week, and serum samples were collected from all euthanized bats to test for VNAs.
At 13 days postinoculation (dpi), bat 2 (inoculated i.m. with MlV1) developed rabies. Within 17 dpi, bat 3 (inoculated i.m. with MlV1) and bat 22 (inoculated i.m. with LnV1) developed rabies. Bat 21 (inoculated i.m. with LnV1) developed clinical signs compatible with RABV infection at 17 dpi. Despite multiple attempts to obtain an unequivocal diagnosis for bat 21, both the dFAT and quantitative PCR (qPCR) provided inconsistent results. Thus, we did not include bat 21 in our analysis. None of the bats inoculated i.m. with EfV2 developed rabies ( Table 1) . No significant difference (P Ն 0.5) was found when comparing the incubation times between RABV variants following the primary i.m. inoculation.
Regardless of the infecting variant, RABV was not found in the saliva of any bat inoculated i.m. Although bats 2 and 22 were negative for VNAs, bat 3 had a low titer (0.5 IU) for anti-rabies virus VNAs.
RABV was present in the saliva of bats that developed rabies following an s.c. inoculation. To better understand how the route of inoculation may affect the disease process, we designed an experiment to assess an s.c. route of inoculation using three different bat RABVs. Fifteen little brown bats were separated into three groups of five bats each and inoculated s.c. with 10 4 TCID 50 s of either MlV1, EfV2, or LnV1. Two of the 15 bats inoculated s.c. developed rabies. Bat 20, which received EfV2, and bat 30, which received LnV1, developed clinical signs compatible with rabies virus infection at 43 and 51 dpi, respectively (Table 1) . A significant difference ( 2 ϭ 6.6, degrees of freedom ϭ 1, P Յ 0.010) was present when comparing the number of bats that developed rabies following an i.m. inoculation (n ϭ 7) and the number of bats that developed rabies following an s.c. inoculation (n ϭ 2).
Virus was found in the saliva of bats 20 and 30 on multiple occasions. Virus was isolated from the oral swab of bat 20 12 and 13 days prior to the development of clinical signs. Virus was first isolated from an oral swab of bat 30 18 days prior to the development of clinical signs.
Blood was collected during euthanasia, at the terminal stage of disease. VNA was not detected in bat 30 (inoculated s.c. with LnV1), but VNA (32 IU) was present in the serum of bat 20.
Prior RABV inoculation was not always protective against i.m. challenge. To evaluate the impact that a previous exposure to RABV may have on subsequent RABV exposure(s), all animals that survived the primary inoculation were challenged with 10 4 TCID 50 s of homologous RABV (MlV1). Bats were inoculated i.m. 6 months after the primary inoculation. Twelve of the 17 (71%) bats that survived the primary inoculation remained healthy following the 6-month challenge. Four of the bats previously inoculated i.m. with EfV2 developed clinical rabies (12, 12, 16 , and 23 days after the challenge inoculation), and one bat initially inoculated s.c. with LnV1 developed rabies 14 days after the challenge inoculation.
Despite oral swab specimen collection biweekly and immediately prior to euthanasia, RABV was not detected in any of the samples. Production of VNAs at the terminal bleed was negligible. The incubation time in bats that developed rabies following the challenge inoculation was similar to that in bats that developed rabies after the primary inoculation (Table 1) .
Although bats inoculated i.m. with EfV2 survived the primary exposure, 80% developed rabies following the challenge with MlV1. This is twice the number that developed rabies following a primary i.m. exposure to MlV1. Although no significant difference was noted (P ϭ 0.19), this trend suggests that exposure to certain RABVs may increase the susceptibility to infection when challenged with a homologous RABV. However, additional research is required to support this hypothesis.
RABV dissemination may depend on the route of exposure, incubation time, and infecting RABV. Although i.m. inoculation is believed to be the most common route of RABV transmission between terrestrial mammals, it may be different among chiropterans (17, 18) On the basis of our data, i.m. inoculation is more likely to result in clinical infection yet is less likely to result in dissemination of the virus to the salivary glands. Centrifugal spread to the salivary glands is integral for the maintenance of RABV in nature, and thus, a lack of dissemination through saliva would result in a dead-end host.
To compare the virulence of homologous and heterologous RABVs, three RABV variants were inoculated either i.m. or s.c. To ascertain the tropism of the RABV as a result of the variant and route of inoculation, bats were necropsied and specimens of several tissues were collected for cryosectioning and tested for the presence of RABV via dFAT and qPCR (Tables 2 and 3 ).
The greatest numbers of RABV antigen-positive tissues were collected from bats inoculated s.c. (bats 20 and 30) or inoculated i.m. with LnV1 (bat 22). Extensive centrifugal spread was evident in bats with the longest incubation periods or following inoculation with the putatively more virulent RABV, LnV1. There was a significant difference (P ϭ 0.008) in dissemination between longer (Ͼ23 dpi) and shorter (Ͻ17 dpi) incubation times. Additionally, a significant difference (P Յ 0.05) was noted when comparing homologous and heterologous virus dissemination.
With the exception of the salivary glands (SGs) and tissues of neurological origin, the other tissues did not contain RABV antigen; only the nerves coursing through the tissues possessed RABV antigen. The anterior spinal cord (ASC), left sciatic nerve (LSN), and right sciatic nerve (RSN) were positive for rabies virus antigen in all cryostat sections examined. The ASC was the only tissue that was positive for both viral RNA and RABV antigen (N protein) in all samples. Regardless of the route or variant, the sample that contained the largest amount of viral RNA was the ASC, with the cycle threshold values ranging from 15 to 16, equal to 10 8 copies.
DISCUSSION
Human rabies cases as a result of vaccine failure have not been reported following the use of cell culture rabies vaccines (15) . The current vaccine is protective against all rabies virus variants when administered i.m. or s.c. (19) . However, the protection afforded a bat following a previous exposure to RABV is unknown. Previous studies have demonstrated that the route of inoculation can be important in predicating survival (20, 21) . Ndaluka (2011) re-ported that intranasal inoculation of RABV in mice was highly pathogenic (21) . Conversely, exposing bats to aerosolized RABV did not result in rabies virus infection. Despite the presence of VNAs, previous aerosol exposure was not protective following an i.m. challenge (20) . Clinical RABV infection is more likely following inoculation with higher viral titers (17, 21) . Indeed, the route to clinical RABV infection is multifactorial. Due to their unique ecology, bats may be exposed to rabies several times during their lives via multiple exposure routes, such as the aerosol route (during echolocation and sound production), as well as the subcutaneous (during grooming) and intramuscular (during fighting) routes. Although aerosol exposure is not protective against an i.m. RABV challenge, previous i.m. and s.c. exposure may provide some level of protection against future RABV exposures (17, 21) .
This study was designed to better understand the maintenance of bat RABV in nature and its impact on public health. Big brown bats (Eptesicus fuscus), little brown bats (Myotis lucifugus), and Mexican free-tailed bats (Tadarida brasiliensis) are the most common bat species in the United States. Although these species have the most frequent interaction with humans and domestic animals, the L. noctivagans and closely related Pipistrellus subflavus RABV is associated with the majority of human rabies virus infections in the United States and Canada (5, 6). However, unlike Mexican freetailed bats, big brown bats, and little brown bats, silver-haired bats are not in frequent contact with humans. Prior to the emergence of white nose syndrome (WNS), 26% and 69% of the bats submitted to the New York State Department of Health (NYSDOH) Rabies Laboratory were little brown bats and big brown bats, respectively (22) . These data are similar to those from most public health laboratories in the United States (6) . Submissions are generally the result of contact between a bat and a human or domestic animal (6, 22) . Following the appearance of WNS, Myotis species accounted for less than 10% of the submissions and greater than 87% were big brown bats. The proportion of silver-haired bats submitted to the NYSDOH Rabies Laboratory has remained stable, comprising approximately 1% of the bats submitted since 1993. Regardless of the presence or absence of WNS, the rate of positivity for rabies virus among bat species has remained consistent between 1993 and 2011. Rabies virus infection was confirmed in 0.8% and 3.5% of the M. lucifugus and E. fuscus bats, respectively. Rabies virus infection was confirmed in 4% of the L. noctivagans and P. subflavus bats submitted to the NYSDOH Rabies Laboratory over the past 18 years. However, due to the low number of submissions to our laboratory, the percentage is disproportionately high compared to the percentages for big brown bats and little brown bats, which are submitted in much greater numbers (6, 22) . Because silver-haired bats are less likely to have contact with other bat species, domestic pets, or humans, the number of human rabies cases associated with LnV1 remains a conundrum.
To determine the susceptibility of M. lucifugus to RABV infections, we inoculated bats with a homologous RABV or one of two heterologous RABVs. Although the lack of significance between the heterologous and homologous infection groups may be the 
No. of RV-positive tissues/total no. of tissues positive (%) result of the small sample size, our study demonstrated that M. lucifugus bats are susceptible to infections with heterologous and homologous RABVs. Our results indicate that primary exposure using a homologous RABV has virulence similar to that of exposure using a heterologous RABV. These results were unexpected; in a previous study with E. fuscus, infection with the homologous RABV was more likely to result in clinical illness than infection with a heterologous RABV (23) . Streicker et al. (2010) reported that although cross-species transmission events were uncommon, they occurred more frequently among closely related species (3). Consequently, less heterogeneity allowed an easier adaptation to a new but closely related host. On the basis of an analysis of data for the partial sequence of cytochrome c oxidase subunit I, M. lucifugus is similarly related to L. noctivagans (83%) and E. fuscus (81%) (3). Analysis of a 1,414-nucleotide region of the rabies virus N gene demonstrated the close relatedness of the M. lucifugus RABV to the L. noctivagans RABV (89.5%) and the E. fuscus RABV (90%). To further pursue the relationship between species and viral relatedness, future studies should include a more distant bat species, such as T. brasiliensis.
While it is doubtful that a bite from an insectivorous bat could penetrate into the muscle of a human, bites between microchiroptera may penetrate muscle during aggressive encounters. Subcutaneous RABV exposure between bats may occur more frequently, e.g., during commensal grooming or routine territorial behaviors that involve biting. Inoculation of RABV into the musculature or subcutaneous tissues via aggression or commensal grooming may be the most likely routes of RABV transmission. How the route of inoculation affects the outcome of disease is unknown. Furthermore, the ability of bat rabies viruses to infect and/or replicate in epithelium or subcutaneous tissues is not well understood.
Mortality (10) . Conversely, Franka et al. (2008) reported an approximately 38% fatality rate following i.m. inoculation with EBLV-1 in a heterologous host (E. fuscus), yet all bats inoculated s.c. survived (25) . These studies reveal that i.m. inoculation is not required to produce clinical rabies virus infection and suggest that s.c. exposure may be the preferred route of inoculation for the maintenance of rabies in bat populations.
In this study, M. lucifugus bats did not develop rabies following s.c. inoculation with a homologous RABV, yet they were susceptible to s.c. exposure with a heterologous RABV. The variation between this and the previous experiments may be multifactorial, including the lyssavirus to which the animal was exposed, the species of bat, previous exposure in nature, and the health of the bat.
Rabies virus was intermittently isolated from the oral swab specimens obtained from the two bats that developed rabies following s.c. inoculation. Virus was detected up to 18 days before clinical signs compatible with RABV infection were first noted. This is considerably longer than the length of time in previous studies, in which RABV was detected in saliva within 10 days of the appearance of clinical signs (14, 18, 26) .
In the present study, primary inoculation with the homologous RABV may have provided the immune priming necessary for surviving a subsequent exposure. This was not apparent following primary inoculation with the two heterologous RABVs. In fact, primary i.m. inoculation with EfV2 (group 3) appeared to have increased the susceptibility to the secondary homologous RABV inoculation. The number of bats in group 3 that developed rabies was twice the number of bats that developed rabies following primary inoculation with the homologous RABV (group 1). To the best of our knowledge, increased susceptibility to RABV following a primary heterologous RABV inoculation has not been demonstrated in previous bat RABV studies.
The increased susceptibility may be the result of immune suppression and evasion, lack of available antibody, or antibody enhancement. RABV is capable of immune subterfuge via decreasing or delaying the immune response or evading the immune system completely (27, 28) . Previous studies have demonstrated that the ability to avert the immune system is not equivalent among RABV variants (4, 6, 8, 9) . A primary i.m. exposure to EfV2 may be more immune modulating than exposure to another bat RABV. Thus, an impaired ability to mount an innate or humoral response following the secondary challenge could provide the virus with an increased opportunity for infection. Alternatively, VNAs produced after the primary inoculation may have been bound to RABV antigen at the time of the second inoculation and thus unavailable to prevent infection.
Antibody enhancement has previously been reported following RABV exposure (29) (30) (31) . Animals inadequately immunized or lacking passive immunization developed rabies more rapidly than their properly immunized or immunocompetent counterparts. Antibody enhancement may have played a role in the development of clinical infection in bats first inoculated i.m. with EfV2. However, since serum was not collected following the primary inoculation, the presence of VNAs following the primary inoculation was undetermined. To determine if antibody enhancement occurs during rabies virus infection in bats, considerable additional research is required. Baer and Bales (1967) suggested that lengthened incubation times allowed the virus to replicate to higher titers in the brain and peripheral tissues and increased centrifugal dissemination (24) . Our results investigating RABV antigen dissemination support greater dissemination following longer incubation times and heterologous RABV infections. However, using the more sensitive qPCR technique to assay the viral load in tissues, no significant difference was found between the groups.
The presence or absence of VNAs at the terminal bleed in this study was not significantly impacted by the route of exposure. The high titer present in bat 20 may have been due to a previous exposure in the wild. One drawback of this study design was the inability to collect preinoculation and routine samples for serology. However, it is clear from this study that the lack of VNAs cannot corroborate rabies virus naiveté.
Viral antigen and RNA were present in multiple tissues, including the salivary glands. However, virus could be isolated only from the saliva of bats that developed clinical disease following s.c. inoculation and, thus, longer incubation times. Following s.c. inoculation, less virus may be available to infect the nerves coursing through the subcutaneous or muscle tissues. Alternatively, the decreased number of motor nerves in the s.c. tissue may affect the ability of RABV to infect the central nervous system (CNS). This could diminish centripetal spread, resulting in less virus entering the CNS and brain and providing the opportunity for increased viral replication and dissemination prior to clinical illness. The additional time could allow the virus time to replicate to levels that result in shedding in saliva. Although viral RNA and antigen were present in the salivary glands of most bats that developed rabies, there was no infectious virus found in the saliva of i.m. inoculated bats. The decreased incubation time may have allowed the virus to have time to disseminate to the salivary glands but not the time to replicate and be shed in the saliva. Alternatively, infectious virus may have been immunologically cleared prior to virus isolation. However, given the short incubation times, this is unlikely.
The current study demonstrates the variability in pathogenesis and clinical disease following experimental homologous and heterologous RABV inoculation in Myotis lucifugus bats. The extended incubation time following subcutaneous inoculation allowed increased RABV dissemination, thereby resulting in infectious saliva and the ability to transmit disease. The saliva of bats inoculated via the i.m. route was negative for infectious RABV, thus resulting in a dead-end host. These results suggest that although the subcutaneous route of inoculation may decrease the incidence of disease, it is more likely to result in disease transmission. Additionally, the susceptibility of M. lucifugus to infection with LnV1 suggests an additional way in which humans may be exposed to the silver-haired bat virus. Increasing our understanding of RABV maintenance in bats will expand our knowledge of public health risks and transmission of zoonotic diseases.
